Literature DB >> 12709901

Effects of curcumin on cyclosporine-induced cholestasis and hypercholesterolemia and on cyclosporine metabolism in the rat.

Michael Deters1, Til Klabunde, Hartmut Meyer, Klaus Resch, Volkhard Kaever.   

Abstract

Former studies have shown that curcumin, which can be extracted from different Curcuma species, is able to stimulate bile flow and to reduce hypercholesterolemia. We investigated in a subchronic bile fistula model the ability of curcumin to reduce cyclosporine-induced cholestasis and hypercholesterolemia. Male Wistar rats were daily treated with curcumin (100 mg/kg p. o.), cyclosporine (10 mg/kg i. p.), and a combination of curcumin with cyclosporine. After two weeks a bile fistula was installed into the rats to measure bile flow and biliary excretion of bile salts, cholesterol, bilirubin, cyclosporine and its main metabolites. Blood was taken to determine the concentration of these parameters in serum or blood. Cyclosporine reduced bile flow (-14 %) and biliary excretion of bile salts (-10 %) and cholesterol (-61 %). On the other hand, cyclosporine increased serum concentrations of cholesterol and triglycerides by 32 % and 82 %, respectively. Sole administration of curcumin led to a slight decrease of bile flow (-7 %) and biliary bile salt excretion (-12 %), but showed no effect on biliary excretion of cholesterol and serum lipid concentration. When curcumin was given simultaneously with cyclosporine, the cyclosporine-induced cholestasis was enhanced but the cyclosporine-induced hyperlipidemia was not affected. Neither the biliary excretion nor the blood concentration of cyclosporine was influenced by curcumin. The blood concentration of the main cyclosporine metabolites, however, was lowered by half while their biliary excretion was strongly increased by curcumin. From these results we conclude that curcumin is not able to prevent cyclosporine-induced cholestasis and hyperlipidemia after prolonged administration in bile fistula rats.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709901     DOI: 10.1055/s-2003-38870

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  4 in total

1.  Effects of curcumin on reflux esophagitis in rats.

Authors:  Sirima Mahattanadul; Nisaudah Radenahmad; Narubodee Phadoongsombut; Thitima Chuchom; Pharkphoom Panichayupakaranant; Shingo Yano; Wantana Reanmongkol
Journal:  J Nat Med       Date:  2006-04-28       Impact factor: 2.343

Review 2.  Metabolic and cardiovascular complications in the liver transplant recipient.

Authors:  Laura De Luca; Rachel Westbrook; Emmanuel A Tsochatzis
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

3.  Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse.

Authors:  Matteo Micucci; Rita Aldini; Monica Cevenini; Carolina Colliva; Silvia Spinozzi; Giulia Roda; Marco Montagnani; Cecilia Camborata; Luca Camarda; Alberto Chiarini; Giuseppe Mazzella; Roberta Budriesi
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

4.  Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation.

Authors:  Fan Yang; Xiaowen Tang; Lili Ding; Yue Zhou; Qiaoling Yang; Junting Gong; Guangyun Wang; Zhengtao Wang; Li Yang
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.